ATE345808T1 - Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen - Google Patents
Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungenInfo
- Publication number
- ATE345808T1 ATE345808T1 AT03766078T AT03766078T ATE345808T1 AT E345808 T1 ATE345808 T1 AT E345808T1 AT 03766078 T AT03766078 T AT 03766078T AT 03766078 T AT03766078 T AT 03766078T AT E345808 T1 ATE345808 T1 AT E345808T1
- Authority
- AT
- Austria
- Prior art keywords
- apolipoprotein
- treatment
- diseases
- derivated
- polypeptide
- Prior art date
Links
- 102100030762 Apolipoprotein L1 Human genes 0.000 title 1
- 101000793429 Homo sapiens Apolipoprotein L1 Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 102000007592 Apolipoproteins Human genes 0.000 abstract 3
- 108010071619 Apolipoproteins Proteins 0.000 abstract 3
- 241000223104 Trypanosoma Species 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/101—Bovine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE200200465 | 2002-08-02 | ||
| BE200200649 | 2002-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE345808T1 true ATE345808T1 (de) | 2006-12-15 |
Family
ID=31496437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03766078T ATE345808T1 (de) | 2002-08-02 | 2003-08-04 | Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7585511B2 (de) |
| EP (1) | EP1534320B1 (de) |
| AT (1) | ATE345808T1 (de) |
| AU (1) | AU2003254426A1 (de) |
| DE (1) | DE60309888T2 (de) |
| DK (1) | DK1534320T3 (de) |
| ES (1) | ES2278201T3 (de) |
| PT (1) | PT1534320E (de) |
| WO (1) | WO2004012757A2 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039645A1 (en) * | 2005-10-06 | 2007-04-12 | Vib Vzw | African trypanosomiasis therapy with a nanobody-conjugated human trypanolytic factor |
| WO2008063603A2 (en) | 2006-11-20 | 2008-05-29 | President And Fellows Of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
| WO2009124941A2 (en) * | 2008-04-07 | 2009-10-15 | Aarhus Universitet | Trypanocidal compounds targeted to trypanosomes interior |
| WO2010129267A2 (en) | 2009-04-27 | 2010-11-11 | University Of Georgia Research Foundation, Inc. | Anti-trypanosomal peptides and uses thereof |
| CA2767646C (en) | 2009-07-10 | 2019-01-29 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| US20110030078A1 (en) * | 2009-07-31 | 2011-02-03 | New York University | Trypanosome resistant non-human transgenic animal |
| WO2011020497A1 (en) * | 2009-08-18 | 2011-02-24 | Universite Libre De Bruxelles | C-terminal mutant of apolipoprotein l-i and its therapeutical or prophylactic use |
| WO2011020865A1 (en) * | 2009-08-18 | 2011-02-24 | Universite Libre De Bruxelles | Apolipoprotein l- i variants and their use |
| US9023355B2 (en) * | 2010-04-13 | 2015-05-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| US9828637B2 (en) * | 2010-04-18 | 2017-11-28 | Wake Forest University Health Sciences | Methods of predicting predisposition to or risk of kidney disease |
| USRE49076E1 (en) | 2010-04-18 | 2022-05-17 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| US20130251740A1 (en) * | 2010-10-26 | 2013-09-26 | Rockefeller University (The) | Immunogenic agents |
| WO2012095508A1 (en) * | 2011-01-13 | 2012-07-19 | Universite Libre De Bruxelles | Apol3 for use in the treatment of trypanosoma infectious diseases |
| EP2489365A1 (de) * | 2011-02-17 | 2012-08-22 | Université Libre de Bruxelles | Wildtyp-Apolipoprotein l-i zur Prävention von Nierenerkrankungen |
| EP2688584A4 (de) * | 2011-03-25 | 2015-05-20 | Univ Columbia | Pegylierte menschliche hdl-partikel und verfahren zu ihrer herstellung |
| US20150291683A1 (en) * | 2012-11-16 | 2015-10-15 | Merck Sharp & Dohme Corp. | Modified apol1 polypeptides |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| US20150307591A1 (en) * | 2012-12-21 | 2015-10-29 | Merck Sharp & Dohme Corp. | On-column refolding and purifying of lipoproteins |
| WO2014137674A1 (en) * | 2013-03-08 | 2014-09-12 | Regeneron Pharmaceuticals, Inc. | Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense |
| CN107105632A (zh) | 2014-11-10 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 肾病动物模型及其治疗剂 |
| KR20180069782A (ko) | 2015-08-03 | 2018-06-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 하전 이온 채널 블록커 및 이용 방법 |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| JP2022527438A (ja) | 2019-03-11 | 2022-06-02 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| EP3937945A4 (de) | 2019-03-11 | 2023-01-04 | Nocion Therapeutics, Inc. | Geladene ionenkanalblocker und verfahren zur verwendung |
| US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| JP2022527731A (ja) | 2019-03-11 | 2022-06-06 | ノシオン セラピューティクス，インコーポレイテッド | エステル置換イオンチャンネル遮断薬および使用方法 |
| JP7513713B2 (ja) | 2019-11-06 | 2024-07-09 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| BR112022008575A2 (pt) | 2019-11-06 | 2022-08-09 | Nocion Therapeutics Inc | Bloqueadores de canal iônico carregado e métodos para uso |
| CN115279731A (zh) | 2020-03-11 | 2022-11-01 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767337A (en) * | 1995-07-31 | 1998-06-16 | Duke University | Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice |
| DK1049767T3 (da) * | 1998-01-08 | 2005-09-19 | Aventis Pharma Inc | En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A) |
-
2003
- 2003-08-04 EP EP03766078A patent/EP1534320B1/de not_active Expired - Lifetime
- 2003-08-04 PT PT03766078T patent/PT1534320E/pt unknown
- 2003-08-04 DK DK03766078T patent/DK1534320T3/da active
- 2003-08-04 AU AU2003254426A patent/AU2003254426A1/en not_active Abandoned
- 2003-08-04 WO PCT/BE2003/000131 patent/WO2004012757A2/en active IP Right Grant
- 2003-08-04 US US10/523,466 patent/US7585511B2/en not_active Expired - Fee Related
- 2003-08-04 ES ES03766078T patent/ES2278201T3/es not_active Expired - Lifetime
- 2003-08-04 AT AT03766078T patent/ATE345808T1/de active
- 2003-08-04 DE DE60309888T patent/DE60309888T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PT1534320E (pt) | 2007-02-28 |
| US20060263348A1 (en) | 2006-11-23 |
| DK1534320T3 (da) | 2007-04-02 |
| ES2278201T3 (es) | 2007-08-01 |
| DE60309888T2 (de) | 2007-06-21 |
| EP1534320A2 (de) | 2005-06-01 |
| AU2003254426A1 (en) | 2004-02-23 |
| WO2004012757A2 (en) | 2004-02-12 |
| WO2004012757A3 (en) | 2004-04-15 |
| EP1534320B1 (de) | 2006-11-22 |
| DE60309888D1 (de) | 2007-01-04 |
| AU2003254426A8 (en) | 2004-02-23 |
| US7585511B2 (en) | 2009-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE345808T1 (de) | Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen | |
| DK1049767T3 (da) | En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A) | |
| ATE416761T1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
| DE60129799D1 (de) | Verfahren zur steigerung des haarwuchses durch wnt polypeptid | |
| DE60114580D1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
| ATE489957T1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| DE60123238D1 (de) | Zusammensetzungen zur behandlung von autoimmunkrankheiten | |
| ATE554169T1 (de) | Smad7-inhibitoren zur behandlung von krankheiten des zns | |
| DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
| ATE290384T1 (de) | Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen | |
| DE60118769D1 (de) | Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten | |
| ATE549026T1 (de) | Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren | |
| ATE551067T1 (de) | Tumstatin zur behandlung von erkrankungen die mit der neumodellierung von atemwegsgewebe zusammenhängen | |
| DE502006001740D1 (de) | Zusammensetzung zur Vorbeugung und Behandlung von Erkältungskrankheiten | |
| ATE315400T1 (de) | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom | |
| ATE541566T1 (de) | Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche | |
| ATE354361T1 (de) | Neue verwendung von prodigiosin zur behandlung von diabetes mellitus | |
| DE60124093D1 (de) | S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen. | |
| ATE337004T1 (de) | Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz | |
| ATE427754T1 (de) | Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen | |
| ATE321545T1 (de) | Calcium-lactat und molkenpermeat zur senkung des triglyceridspiegels | |
| ATE359088T1 (de) | Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten | |
| ATE450293T1 (de) | Verwendung von molkenpermeat zur behandlung des metabolischen syndroms | |
| ATE250417T1 (de) | Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6- isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1534320 Country of ref document: EP |